Exploring A One-Stop Integrated Solution For AAV Vector Clinical Production
Every choice is critical in adeno-associated virus (AAV) vector production. Make the right choices and you can slash time to manufacture clinical-quality drug product to just nine months, but missteps can cause timelines and costs to spiral, delaying access to life-changing medicines and handing advantages to rivals.
In this webinar, we show you how to make the right choices across all the key variables, from the process and cell line, to off-the-shelf plasmids and qualified analytical methods. Viewers will gain a blueprint for a complete platform approach that is consistent, efficient and delivers a process that easily scales up as you move to late-stage GMP production and on the market.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.